Vitiligo — Causes, Symptoms, Diagnosis & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Vitiligo is a chronic acquired autoimmune skin disorder characterised by the progressive loss of melanocytes (pigment-producing cells) from the epidermis, resulting in depigmented (chalk-white) macules and patches on the skin, mucous membranes, and occasionally the hair (leukotrichia). The loss of melanocytes is driven by CD8+ autoreactive T-cells that target melanocyte-specific antigens (including MART-1/Melan-A and HSP70i). Vitiligo is classified as non-segmental (NSV — bilateral, often symmetric, affects any body site, tends to progress) or segmental (SV — unilateral, follows a dermatomal-like pattern, often early onset, stabilises within 1-2 years — different pathophysiology, responds differently to treatment). It affects 1-2% of the global population regardless of sex. While physically harmless, vitiligo has profound psychosocial impact — particularly in individuals with darker skin where contrast is more visible — causing depression, reduced self-esteem, social withdrawal, and occupational discrimination.

Vitiligo results from a convergence of genetic susceptibility, environmental triggers, and immune dysregulation. Genetic factors: vitiligo is strongly polygenic — over 50 susceptibility loci identified; notably shared genetic risk with other autoimmune diseases (HLA-A*02:01, PTPN22, CTLA4, NLRP1 variants). Autoimmune mechanism: activated cytotoxic CD8+ T-cells (specific for melanocyte antigens including MART-1) infiltrate the skin and destroy melanocytes through perforin/granzyme and IFN-gamma/CXCL10 signalling. The JAK-STAT pathway (particularly IFN-gamma → JAK1/JAK2 → STAT1) is central to melanocyte destruction — explaining the efficacy of JAK inhibitors. Environmental and intrinsic triggers: mechanical trauma (Koebner phenomenon — new depigmentation at sites of skin injury), sunburn, emotional stress, and contact with phenolic chemicals (occupational exposure to para-tertiary-butylphenol). Associated autoimmune conditions: autoimmune thyroid disease (Hashimoto's thyroiditis — most common association; present in 15-30% of vitiligo patients), type 1 diabetes, Addison's disease (adrenal insufficiency), alopecia areata, pernicious anaemia, and rheumatoid arthritis — screen for these at diagnosis.

Vitiligo presents as chalk-white (achromic — completely lacking pigment, distinguishing it from hypopigmented conditions which have reduced but not absent pigment) macules and patches with well-defined edges that may gradually enlarge and coalesce. Distribution: non-segmental vitiligo typically affects sun-exposed areas (face — periorbital, perioral; hands and wrists; feet; genitalia), as well as areas subject to friction (elbows, knees, ankles). Acrofacial pattern (perioral and peridigital) is common. Hair involvement (leukotrichia — white hairs within vitiligo patches) indicates destruction of follicular melanocytes and predicts poorer treatment response. Trichrome vitiligo (three zones — white, light-pigmented, normally pigmented) indicates active spread. Confetti vitiligo (small scattered white spots) indicates very active disease with rapid spread. The skin within vitiligo patches is structurally and functionally normal except for melanocyte absence — there is no itch or scale in vitiligo (if present, consider tinea versicolor or other differentials). Vitiligo has significant psychological burden: depression, anxiety, reduced quality of life — particularly in those with visible distribution and darker baseline skin tone where contrast is most pronounced.

Vitiligo is primarily a clinical diagnosis — made by the characteristic appearance of chalk-white, well-demarcated macules and patches. Wood's lamp (UV-A lamp, 365 nm): enhances the visibility of depigmented patches in lighter-skinned patients — vitiligo patches show bright fluorescent white accentuation under Wood's lamp, confirming complete melanocyte loss (distinguishes from hypopigmentation). Dermoscopy: perifollicular pigmentation (a positive prognostic sign indicating follicular melanocyte survival and potential for repigmentation); absence of pigmentation in the patch; inflammatory border in active lesions. Differential diagnoses to consider: pityriasis versicolor (hypopigmented, not achromic; scale present; KOH positive for Malassezia), post-inflammatory hypopigmentation (achromic patches at sites of previous inflammation; history of psoriasis, eczema), pityriasis alba (poorly defined, slightly scaly, light-brown hypopigmented patches in children), chemical leucoderma (same distribution as chemical exposure), naevus depigmentosus (stable from birth), Vogt-Koyanagi-Harada syndrome (uveitis, vitiligo, alopecia, and meningism). Blood tests at diagnosis: TFTs (thyroid function — TSH + free T4), anti-thyroid peroxidase antibodies, fasting glucose/HbA1c, vitamin B12 (pernicious anaemia association), and ANA (if SLE suspected).

Treatment aims at stopping progression (immunosuppression) and stimulating repigmentation from surviving follicular melanocytes (phototherapy and other activating treatments). Topical treatments: topical corticosteroids (high-potency — mometasone, betamethasone; useful for small active patches; risk of atrophy with prolonged use — not suitable for face or folds); topical calcineurin inhibitors (tacrolimus 0.1% ointment or pimecrolimus 1% cream — preferred for face, eyelids, neck, genitalia; anti-inflammatory without risk of skin atrophy; NICE-approved for vitiligo on face and sensitive areas); topical JAK inhibitors (ruxolitinib 1.5% cream — Opzelura — FDA-approved June 2022 and MHRA-approved 2023 for non-segmental vitiligo; most effective topical treatment for repigmentation; inhibits JAK1/2 and IFN-gamma CXCL10 axis; superior to calcineurin inhibitors in clinical trials). Phototherapy: narrowband UVB (NB-UVB — wavelength 311-313 nm) is the most effective and widely used systemic treatment for widespread non-segmental vitiligo — stimulates melanocyte proliferation and migration from hair follicle reservoirs; conducted 2-3 times weekly for 6-24 months; best response on face, trunk, and proximal limbs; poor response on hands, feet, and mucosal sites. Excimer laser (308 nm): targeted NB-UVB for localised vitiligo — delivered to small areas without exposing surrounding skin. PUVA (psoralen + UVA): effective but more side effects than NB-UVB — now less commonly used. Systemic immunosuppression: oral corticosteroids (mini-pulse prednisolone — used for rapidly progressive/spreading vitiligo to halt activity); JAK inhibitors (oral ruxolitinib, baricitinib — under investigation for severe/refractory vitiligo; not yet licensed for systemic use in vitiligo). Surgical repigmentation (only for stable vitiligo — no new lesions for 12-24 months): split-thickness skin grafting; melanocyte-keratinocyte transplant procedure (MKTP — cell suspension transplantation); follicular unit extraction and transplantation — for limited stable patches. Camouflage: medical-grade camouflage creams (British Red Cross provides service); self-tanning products for cosmetic improvement; useful for psychosocial wellbeing. Depigmentation: irreversible depigmentation of remaining pigmented skin with monobenzyl ether of hydroquinone (MBEH cream) — considered for extensive (more than 50% body surface) vitiligo as a cosmetic measure to achieve uniform skin tone; permanent and irreversible.

Vitiligo causes significant psychological and potential physical complications despite being a benign, non-contagious condition. Psychological complications: the most significant complications of vitiligo are psychological — depression affects 20-35% and anxiety 35-50% of vitiligo patients; self-consciousness, reduced self-esteem, and social withdrawal are prominent; relationship difficulties, occupational avoidance, and impaired quality of life are common; social stigma — particularly in cultures where skin tone carries cultural significance — can be severe and cause significant discrimination. The psychological burden correlates with lesion extent, facial or genital involvement, and age of onset (adolescents are particularly vulnerable). Photodamage on depigmented skin: the complete absence of melanin in vitiligo patches means loss of UV protection — affected areas are highly susceptible to sunburn, and the risk of sun-induced skin cancer (including melanoma on depigmented skin) is theoretically increased; diligent sunscreen use on all depigmented areas is essential year-round. Koebner phenomenon: physical trauma (cuts, sunburn, friction) on unaffected skin can trigger new vitiligo patches in the traumatised area in susceptible individuals — particularly relevant for occupational and sports injuries. Associated autoimmune conditions: vitiligo is associated with increased risk of autoimmune thyroid disease (Hashimoto's thyroiditis, Grave's disease — found in 20-30%), T1 diabetes, pernicious anaemia, alopecia areata, and Addison's disease — requiring periodic screening.

Avoid the Koebner phenomenon — minimise skin trauma: wear sunscreen (SPF 30 or above) on vitiligo patches daily (depigmented skin lacks UV protection from melanin and burns more readily); avoid mechanical friction on affected areas; treat cuts and abrasions promptly; avoid wearing tight clothing over vitiligo patches. Strict sun protection on vitiligo patches prevents painful sunburn and may reduce Koebner-mediated spread. Screen for and manage associated autoimmune conditions — treat hypothyroidism adequately (uncontrolled thyroid disease may worsen vitiligo activity). Psychological support — address the psychosocial impact early; connect with patient support groups (Vitiligo Society UK, Vitiligo Support International). Minimise known triggers where possible — reduce emotional stress (stress-reduction techniques including mindfulness, CBT); avoid chemical exposure (phenolic compounds). Maintain vitamin D levels (screen annually) — vitiligo patients, who often avoid sun exposure, are at risk of deficiency.

Consult your GP for new white patches of skin that are not resolving — even if asymptomatic, vitiligo should be confirmed by a clinician and associated autoimmune conditions screened for (thyroid disease is most important). Request dermatology referral for: rapidly spreading vitiligo (to initiate systemic immunosuppression to halt spread), vitiligo causing significant psychological distress (referral for phototherapy or JAK inhibitor treatment), and stable vitiligo suitable for surgical repigmentation. Seek urgent GP assessment for symptoms suggesting associated autoimmune conditions: fatigue and weight gain (hypothyroidism), polydipsia and polyuria (type 1 diabetes), severe fatigue with hyperpigmentation and postural hypotension (Addison's disease — adrenal insufficiency). Vitiligo in children should always be assessed by a paediatric dermatologist to confirm the diagnosis, screen for associated autoimmune conditions, and advise on age-appropriate treatment and psychosocial support.